Human transthyretin (TTR) is a 55 kDa homotetramer plasma transport protein for thyroxine T4 and for retinol, through the association with retinol binding protein, in the blood and cerebrospinal fluid. TTR mutants have been implicated in familial amyloid polyneuropathy (FAP), a life-threatening multisystem disorder characterised by extracellular depositions of amyloid fibrils. It is an irreversible and progressive disease and is fatal within 10 years of onset. There are currently more than 80 pathogenic mutations reported for TTR. These mutations alter the protein stability leading to tetramer dissociation and favouring an abnormal monomeric structure, which in turn polymerises into unknown intermediates and finally into amyloid fibrils.
